Neovascular Age-related Macular Degeneration
Conditions
Keywords
KH902, age-related macular degeneration (AMD), choroidal neovascularization (CNV), intravitreal injection, best corrected visual acuity (BCVA), central retinal thickness
Brief summary
This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.
Detailed description
AMD is the leading cause of severe vision loss in people over the age of 65 in the United States and other western countries. A quantity of documents indicate that neovascularization promoted by VEGF is main cause of visual acuity decline. Patients are starving for a new drug which can notably improve VA with less administration frequency and lower treatment cost. The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The pre-clinical researches and phase I study show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF. This study is designed to confirm the efficacy and safety of multiple injections of KH902 at variable dosing regimen in patients with CNV due to neovascular AMD. Based on the characteristics of KH902 and results from KH902 Phase I study as well as reference to clinical trials of similar drugs, it is determined that KH902 is administrated at 0.5mg/eye/time and 2.0mg/eye/time.
Interventions
BIOLOGICALintravitreal injection of KH902
Sponsors
Beijing DMS Pharma Ltd.
The Digital Angiography Reading Center (DARC)
Chengdu Kanghong Biotech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed the ICF; Age ≥ 50 years of either gender; * Active primary or recurrent lesions with subfoveal or juxtafoveal CNV secondary to neovascular AMD in the study eye; * Lesion size ≤ 12 disc areas in either eye; * BCVA of the study eyes between 73 and 24 letters, inclusively, and the BCVA of fellow eyes ≥ 19 letters; * Clear ocular media and adequate pupil dilation. * If both eyes were eligible, only one was selected.
Exclusion criteria
* History of vitreous hemorrhage, retinal detachment or macular hole, presence of retinal pigment epithelial tear, retinal macular traction or macular epiretinal membrane in the study eye; * Subfoveal scar or atrophy in the study eye; * Subretinal hemorrhage in the study eye; * Uncontrolled glaucoma in either eye; * Active inflammation or infection in either eye; * Previous drug treatment, either anti-VEGF drugs or steroid derivatives, and/or, previous ophthalmologic operation or laser therapy in the study eye; * History of surgery within one month preceding enrollment; * Any uncontrolled clinical disorders; * Patients of child-bearing potential do not adopted adequate contraception methods; * Pregnant or nursing women; * Patients need to exclude in the opinion of investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in BCVA | at 3-month |
| The incidence rate of adverse event | at 3-month |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in central retinal thickness | at 3-month and 12-month |
Countries
China
Outcome results
None listed